Posted by Michael Wonder on 16 Oct 2023
Editas Medicine granted FDA regenerative medicine advanced therapy designation for EDIT-301 for the treatment of severe sickle cell disease
16 October 2023 - Editas Medicine today announced that the US FDA granted regenerative medicine advanced therapy designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease.
The FDA previously granted orphan drug designation and rare paediatric disease designation to EDIT-301 for the treatment of sickle cell disease and beta thalassaemia.
